230 related articles for article (PubMed ID: 33152384)
1. CB
Mielnik CA; Lam VM; Ross RA
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 106():110163. PubMed ID: 33152384
[TBL] [Abstract][Full Text] [Related]
2. Translational potential of allosteric modulators targeting the cannabinoid CB
Lu D; Immadi SS; Wu Z; Kendall DA
Acta Pharmacol Sin; 2019 Mar; 40(3):324-335. PubMed ID: 30333554
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias.
Manning JJ; Green HM; Glass M; Finlay DB
Neuropharmacology; 2021 Aug; 193():108611. PubMed ID: 34000272
[TBL] [Abstract][Full Text] [Related]
4. Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.
Nguyen T; Li JX; Thomas BF; Wiley JL; Kenakin TP; Zhang Y
Med Res Rev; 2017 May; 37(3):441-474. PubMed ID: 27879006
[TBL] [Abstract][Full Text] [Related]
5. Synthetic Cannabinoid Receptor Agonists and Antagonists: Implication in CNS Disorders.
Manera C; Arena C; Chicca A
Recent Pat CNS Drug Discov; 2016; 10(2):142-156. PubMed ID: 27193072
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.
Rock EM; Sticht MA; Duncan M; Stott C; Parker LA
Br J Pharmacol; 2013 Oct; 170(3):671-8. PubMed ID: 23902479
[TBL] [Abstract][Full Text] [Related]
7. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.
Laprairie RB; Bagher AM; Rourke JL; Zrein A; Cairns EA; Kelly MEM; Sinal CJ; Kulkarni PM; Thakur GA; Denovan-Wright EM
Neuropharmacology; 2019 Jun; 151():1-12. PubMed ID: 30940536
[TBL] [Abstract][Full Text] [Related]
8. Aiming for allosterism: Evaluation of allosteric modulators of CB1 in a neuronal model.
Straiker A; Mitjavila J; Yin D; Gibson A; Mackie K
Pharmacol Res; 2015 Sep; 99():370-6. PubMed ID: 26211948
[TBL] [Abstract][Full Text] [Related]
9. CB
Trexler KR; Eckard ML; Kinsey SG
Pharmacol Biochem Behav; 2019 Feb; 177():27-33. PubMed ID: 30597181
[TBL] [Abstract][Full Text] [Related]
10. The synthetic CB
Coronado-Álvarez A; Romero-Cordero K; Macías-Triana L; Tatum-Kuri A; Vera-Barrón A; Budde H; Machado S; Yamamoto T; Imperatori C; Murillo-Rodríguez E
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Aug; 110():110301. PubMed ID: 33741446
[TBL] [Abstract][Full Text] [Related]
11. Real-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action.
Cawston EE; Redmond WJ; Breen CM; Grimsey NL; Connor M; Glass M
Br J Pharmacol; 2013 Oct; 170(4):893-907. PubMed ID: 23937487
[TBL] [Abstract][Full Text] [Related]
12. The great divide: Separation between in vitro and in vivo effects of PSNCBAM-based CB
Gamage TF; Farquhar CE; Lefever TW; Thomas BF; Nguyen T; Zhang Y; Wiley JL
Neuropharmacology; 2017 Oct; 125():365-375. PubMed ID: 28803965
[TBL] [Abstract][Full Text] [Related]
13. Modern approaches to the development of synthetic cannabinoid receptor probes.
Saldaña-Shumaker SL; Grenning AJ; Cunningham CW
Pharmacol Biochem Behav; 2021 Apr; 203():173119. PubMed ID: 33508249
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.
Sholler DJ; Huestis MA; Amendolara B; Vandrey R; Cooper ZD
Pharmacol Biochem Behav; 2020 Dec; 199():173059. PubMed ID: 33086126
[TBL] [Abstract][Full Text] [Related]
15. CB1 Receptor Negative Allosteric Modulators as a Potential Tool to Reverse Cannabinoid Toxicity.
Flavin A; Azizi P; Murataeva N; Yust K; Du W; Ross R; Greig I; Nguyen T; Zhang Y; Mackie K; Straiker A
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675703
[TBL] [Abstract][Full Text] [Related]
16. Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor.
Khajehali E; Malone DT; Glass M; Sexton PM; Christopoulos A; Leach K
Mol Pharmacol; 2015 Aug; 88(2):368-79. PubMed ID: 26044547
[TBL] [Abstract][Full Text] [Related]
17. Assessing Allosteric Modulation of CB
Scott CE; Kendall DA
Methods Enzymol; 2017; 593():317-342. PubMed ID: 28750809
[TBL] [Abstract][Full Text] [Related]
18. Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.
Laprairie RB; Kulkarni PM; Deschamps JR; Kelly MEM; Janero DR; Cascio MG; Stevenson LA; Pertwee RG; Kenakin TP; Denovan-Wright EM; Thakur GA
ACS Chem Neurosci; 2017 Jun; 8(6):1188-1203. PubMed ID: 28103441
[TBL] [Abstract][Full Text] [Related]
19. In vivo evaluation of the CB
Mustafa M; Donvito G; Moncayo L; Swafford A; Poklis J; Grauer R; Olszewska T; Ignatowska-Jankowska B; Kendall DA; Lu D; Lichtman AH
Pharmacol Biochem Behav; 2020 Mar; 190():172840. PubMed ID: 31899221
[TBL] [Abstract][Full Text] [Related]
20. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
